Both in Biotechnology
Biogen vs Exelixis
Over the past year BIIB returned +67.5% and EXEL returned +82.3%; their daily moves had a correlation of 0.34.
BIIB +67.5% EXEL +82.3%Growth of $1, one year, split-adjusted
| Metric | BIIB | EXEL |
|---|---|---|
| Price | $253.62 | $69.39 |
| Market cap | $37.49B | $16.93B |
| Today | +1.59% | +4.82% |
| 1 month | +13.8% | +19.8% |
| 6 months | +35.6% | +58.9% |
| Year to date | +44.1% | +58.3% |
| 1 year | +71.5% | +76.0% |
| Revenue growth (YoY) | +10.6% | +10.2% |
| Gross margin | 73.3% | 96.0% |
| Net margin | −0.7% | 33.1% |
| P/E (TTM) | 107.9× | 19.1× |
| Price / sales | 3.6× | 6.8× |
| Net cash | -$6.39B | $892.0M |
| Dividend yield | — | — |
| Volatility (60d) | 27.9% | 27.5% |
| Short % of float | 3.7% | 11.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).